Provectus Biopharmaceuticals

OverviewSuggest Edit

Provectus Biopharmaceuticals, Inc. is a development stage biopharmaceutical company that is primarily engaged in developing ethical pharmaceuticals for oncology and dermatology indications. The Company focuses on developing its prescription drug candidates PV-10 and PH-10. Provectus is developing PV-10 for treatment of several life threatening cancers including metastatic melanoma, liver cancer, and breast cancer. The Company is developing PH-10 to provide minimally invasive treatment of chronic severe skin afflictions such as psoriasis and atopic dermatitis, a type of eczema.

TypePublic
Founded2002
HQKnoxville, US
Websiteprovectusbio.com

Latest Updates

Employees (est.) (Dec 2019)2
Revenue (FY, 2015)$0
Share Price (Sept 2020)$0.1 (+23%)
Cybersecurity ratingDMore

Key People/Management at Provectus Biopharmaceuticals

Bruce Horowitz

Bruce Horowitz

Chief Operating Officer
Ed Pershing

Ed Pershing

Chairman of the Board
Eric Wachter

Eric Wachter

Chief Technology Officer
Dominic Rodrigues

Dominic Rodrigues

Vice Chairman of the Board
Heather Raines

Heather Raines

Chief Financial Officer
Jan E. Koe

Jan E. Koe

Board Member
Show more

Provectus Biopharmaceuticals Office Locations

Provectus Biopharmaceuticals has offices in Knoxville and Brentwood
Knoxville, US (HQ)
10025 Investment Dr #250Knoxville
Show all (2)

Provectus Biopharmaceuticals Financials and Metrics

Provectus Biopharmaceuticals Revenue

USD

Net income (Q2, 2020)

(1.6m)

EBIT (Q2, 2020)

(1.2m)

Market capitalization (17-Sept-2020)

34.3m

Closing stock price (17-Sept-2020)

0.1

Cash (30-Jun-2020)

1.5m

EV

57.8m
Provectus Biopharmaceuticals's current market capitalization is $34.3 m.
Annual
USDFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

General and administrative expense

8.7m8.8m11.0m13.3m16.0m5.5m3.3m2.3m

R&D expense

5.0m3.6m5.1m10.7m8.5m8.2m4.7m4.0m

Operating expense total

13.7m12.4m16.1m24.0m24.5m13.7m8.1m6.3m
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Revenue

General and administrative expense

3.2m3.9m2.5m2.3m2.3m2.2m3.1m3.0m2.3m2.2m2.4m2.9m6.1m3.0m3.3m2.5m924.1k728.9k962.7k1.3m829.4k759.3k631.1k438.4k538.8k514.4k

R&D expense

2.0m3.4m1.7m740.5k778.3k1.3m1.2m1.0m1.4m2.3m2.1m2.7m2.4m2.0m2.5m1.9m2.4m2.4m1.9m987.2k528.4k1.0m1.2m1.0m909.4k696.5k

Operating expense total

5.2m7.3m4.1m3.1m3.1m3.5m4.2m4.0m3.7m4.5m4.4m5.6m8.5m5.0m5.8m4.4m3.3m3.1m2.9m2.3m1.4m1.8m1.8m1.4m1.4m1.2m
Annual
USDFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

1.2m15.7m17.4m14.2m1.2m105.5k51.0k590.7k

Accounts Receivable

8.9m55.1k

Prepaid Expenses

978.0k41.2k400.4k370.2k350.2k

Current Assets

19.1m14.7m1.8m958.3k1.0m996.0k
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

14.4m10.8m4.9m4.1m1.8m4.3m4.6m8.3m16.6m18.1m17.8m14.2m23.1m18.9m9.8m4.9m5.2m437.0k1.1m208.3k244.1k130.6k231.9k1.8m1.3m434.8k213.7k1.5m

Accounts Receivable

74.2k3.8k

Prepaid Expenses

53.8k140.8k93.0k45.3k1.2m1.2m1.1m336.9k316.6k187.2k250.5k245.0k325.4k300.7k273.6k207.8k272.0k242.4k169.1k240.4k142.7k

Current Assets

14.5m10.9m5.0m4.1m1.9m4.5m4.7m8.3m16.6m18.1m17.8m15.9m24.5m19.9m10.4m5.4m5.4m887.5k1.5m533.7k744.8k1.4m441.7k2.7m1.9m894.0k528.3k1.6m
USDQ2, 2011

Debt/Equity

0.4 x

Debt/Assets

0.3 x

Financial Leverage

1.4 x
Show all financial metrics

Provectus Biopharmaceuticals Cybersecurity Score

Cybersecurity ratingPremium dataset

D

66/100

SecurityScorecard logo

Provectus Biopharmaceuticals Online and Social Media Presence

Embed Graph

Provectus Biopharmaceuticals News and Updates

Provectus Biopharmaceuticals Announces Presentation of 2-Year Landmark Data from Combination Therapy Trial of PV-10® and KEYTRUDA® for Checkpoint-Naïve Advanced Cutaneous Melanoma at ESMO Virtual Congress 2020

KNOXVILLE, TN, Sept. 17, 2020 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that 2-year landmark survival, response, and safety data from the Company’s Phase 1b/2 study of small molecule autolytic cancer immunotherapy PV-10, an injectable formulation of Provectus’ proprietary rose be…

Provectus Biopharmaceuticals Announces Change to Board of Directors

KNOXVILLE, TN, July 16, 2020 ( ) - Provectus (OTCQB: PVCT) today is pleased to announce the addition of Webster Bailey to the Company's Board of Directors (the "Board"), effective as of July 20, 2020. Mr. Bailey is a member of the board of directors of the Clover Fork Coal Company investment trust (…

Provectus Biopharmaceuticals Announces Discovery of Unique PV-10®-Induced STING Pathway Mechanism for Presentation at American Association for Cancer Research (AACR) 2020 Virtual Annual Meeting II

KNOXVILLE, TN, June 22, 2020 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today is pleased to announce that data from ongoing preclinical study of investigational autolytic cancer immunotherapy PV-10 (rose bengal disodium) is being presented at the American Association for Cancer Research (AACR) 20…

University of Tennessee Haslam College of Business Recognizes Provectus Biopharmaceuticals Chairman Ed Pershing as 2018 Outstanding Entrepreneur

KNOXVILLE, TN, Nov. 12, 2018 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that Ed Pershing, CPA, the Chairman of the Company’s board of directors, was recognized by the Haslam College of Business (HCB) at the University of Tennessee, Knoxville as HCB’s 2018 Outstanding Entrepreneur…

Provectus Biopharmaceuticals Frequently Asked Questions

  • When was Provectus Biopharmaceuticals founded?

    Provectus Biopharmaceuticals was founded in 2002.

  • Who are Provectus Biopharmaceuticals key executives?

    Provectus Biopharmaceuticals's key executives are Bruce Horowitz, Ed Pershing and Eric Wachter.

  • How many employees does Provectus Biopharmaceuticals have?

    Provectus Biopharmaceuticals has 2 employees.

  • Who are Provectus Biopharmaceuticals competitors?

    Competitors of Provectus Biopharmaceuticals include Eczema Honey, Amplia Therapeutics and Ethypharm.

  • Where is Provectus Biopharmaceuticals headquarters?

    Provectus Biopharmaceuticals headquarters is located at 10025 Investment Dr #250Knoxville, Knoxville.

  • Where are Provectus Biopharmaceuticals offices?

    Provectus Biopharmaceuticals has offices in Knoxville and Brentwood.

  • How many offices does Provectus Biopharmaceuticals have?

    Provectus Biopharmaceuticals has 2 offices.